Your Position: Home > Journal List > CHINA MEDICINE > Paper

Effect and safety of atovastatin calcium on dyslipidemia and hypersensitive C-reactive protein in hypertension patients

( views:216, downloads:0 )
Author:
YU Hui-wen(Department of Cardiology,The Fourth Affiliated Hospital of Medical College of Jinan University & Guangzhou Red Cross Hospital,Guangzhou 510220,China)
JIANG Zuo-feng(Department of Cardiology,The Fourth Affiliated Hospital of Medical College of Jinan University & Guangzhou Red Cross Hospital,Guangzhou 510220,China)
WEI Jian-rui(Department of Cardiology,The Fourth Affiliated Hospital of Medical College of Jinan University & Guangzhou Red Cross Hospital,Guangzhou 510220,China)
Journal Title:
CHINA MEDICINE
Issue:
Volume 06, Issue 04, 2011
DOI:
10.3760/cma.j.issn.1673-4777.2011.04.004
Key Word:
Hypertension;Dyslipidemia;C-reactive protein;Atovastatin calcium

Abstract: Objective To investigate the effect and safety of atovastatin calcium on dyslipidemia and hypersensitive C-reactive protein in hypertension patients. Methods One hundred and twenty-eight hypertensive patients with dyslipidedmia were divided into two groups: control group and treatment group. All patients were in low-fat and low-cholesterol diet and received antihypertensive treatment as usual. Patients in treatment group took atovastatin (20 mg/day) for 12 weeks. Systolic blood pressure (SBP), diastolic blood pressure(DBP), serum total glycerin (TG), total cholesterol ( TC ), low-dense-lipoprotein cholesterol ( LDL-C ), high-dense-lipoprotein cholesterol (HDL-C), very low-dense-lipoprotein cholesterol (VLDL-C), hypersensitive C-reactive protein (hs-CRP), creatinin (Cr), glutamate pyruvate transaminase (ALT) and creatine kinase (CK) were measured before and after the treatment. Results In patients with atovastatin treatment, TG was reduced 16%[(1.6 ±1.2)mmoL/L vs (2.0 ±0.9) mmol/L, P < 0.05], TC was reduced 24% [(4 ± 1 ) mmol/L vs (6 ± 1 ) mmoL/L, P < 0.01], LDL-C was reduced 34% [(3 ± 1 ) mmol/L vs (4 ± 1 ) mmol/L, P < 0.01] and hs-CRP was significantly reduced [(2.3 ± 1.5 )mg/L vs (5.3 ± 2.9)mg/L, P < 0.01]. CK increased lightly in two patients with atovastatin treatment and were in normal range in one month although the patients received atovastatin ( 10 mg/day) treatment. Compared to control group, TC, LDL-C, VLDL-C and hs-CRP were significantly reduced in treatment group. There was no significant difference in HDL-C, SBP, DBP, Cr and ALT. Conclusion Atovastatin can decrease hypersensitive C-reactive protein in hypertension patients with dyslipidemia.

  • [1]安宁,谢高强,武阳丰.心脑血管病主要危险因素对其发病和死亡的归因危险.中国慢性病预防与控制,3003,11(1):42-45.
  • [2]高血压患者胆固醇管理临床指导建议专家组.高血压患者胆固醇管理临床指导建议.中华内科学杂志,2010,49(2):186-190.
  • [3]Sever PS,Dahl(o)f B,Poulter NR,et al.Prevention d coronary and stroke events with astorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations,in the AngloScandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):a multicentre randomised controlled trial.Lancet,2003,361(9364):1149-1158.
  • [4]中国成人血脂异常防治指南制定联合委员会.中国成人血脂异常防治指南.中华心血管杂志,2007,35(5):390-419.
  • [5]Tozewski J,Torzewski M,Bowyer DE,et al.C-reactive protein in frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries.Arterioscler Thromb Vasc Bio1,1988,18(9):1386-1392.
  • [6]Nissen SE,Tuzcu EM,Schoenhagen P,et al.Statin therapy,LDL cholesterol,C-reactive protein,and coronary artery disease.N Engl J Med,2005,352(1):29-38.
  • [7]李志勇,李勋.C反应蛋白与冠状动脉粥样硬化性心脏病.医学综述,2008,14(23):3580-3585.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn